# Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

> **NCT05233410** · PHASE3 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Chronic Hand Eczema (CHE)

## Interventions

- **DRUG:** Ruxolitinib cream
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05233410
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01-31
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-09-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision; no safety concerns
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233410, "Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05233410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*